Emerging Treatment Strategies for Metastatic Triple-Negative Breast Cancer

Cytotoxic chemotherapy remains the mainstay of treatment for most patients with metastatic TNBC (mTNBC), but duration of response is often short and median overall survival is only 12 to 18 months. Therefore, it is critical to identify novel treatment strategies to improve outcomes for these patients. In this review article, the authors discuss recent advances in treatment strategies for patients with mTNBC, including the use of immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates.